Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Therapeutic Cancer Vaccines Overview 2017 - Research and Markets

Research and Markets
Posted on: 22 Sep 17

The "Therapeutic Cancer Vaccines Overview" drug pipelines has been added to Research and Markets' offering.

This report consists of a detailed Executive presentation (~100 slides) and MS-Excel work book summarizing current approaches in cancer immunotherapy with an in-depth focus on the therapeutic cancer vaccine category. Included is an analysis of over 300 verified cancer vaccine programs (Phase I-III) delineated by sponsor, sponsor type, mechanism, tumour type, results, and other relevant fields. Detailed case studies are presented for the identified late stage (Phase III) industry sponsored programs e.g. PROSTVAC Bavarian Nordic with presentation of clinical trial data relevant to the Provenge (Sipuleucel-T) reference for FDA approval. This analysis is recommended to any client wishing to understand quickly the commercial landscape of the therapeutic cancer vaccine field within the overview dynamic of cancer immunotherapy.

Cancer is one of the leading causes of death worldwide causing approximately 1 in every 7 deaths. In 2012, 8.2 million people died of the disease with 14 million new cases recorded in that year (WHO Figures). In 2030, the number of new cancer cases is projected to be >22 million (50-70% increase) due to the increasing population age and size.

Cancer immunotherapy (active and passive) aims to harness the body's own immune system in the fight against tumour progression. In the past decade, this strategy has become the most promising in the search for novel cancer therapies. Recent breakthroughs include either tumour specific/bi-specific monoclonal antibodies (mAbs), checkpoint inhibitors, adoptive cell therapy and therapeutic cancer vaccines (peptides, dendritic cells, allogenic cells, autologous cells, oncolytic viruses). For the latter group, Dendreon's Provenge (Sipuleucel-T) was the first therapeutic vaccine approved for any cancer.

Companies Mentioned

  • Advantagene Inc
  • Bavarian Nordic
  • Bioven
  • Gradalis
  • Immunocellular Therapeutics Ltd
  • Immunovative Therapies Ltd
  • NewLink Genetics Corporation
  • Northwest Biotherapeutics
  • OSE Immunotherapeutics
  • Polynoma
  • Recombio
  • Sotio

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 22/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.